TMICC begins new life as global ice-cream leader in positive stock market debut

The Magnum Ice Cream Company (TMICC) began trading in London and Amsterdam ahead of a New York listing, implying an Amsterdam valuation of roughly $9.2bn; Unilever will retain a 19.9% stake to be wound down over five years. TMICC reported 2024 revenue of €7.95bn, adjusted EBITDA €1.34bn (16.9% margin), and adjusted operating profit €964m, with organic sales growth of 2% in 2024 and H1 2025 and a medium-term organic growth target of 3–5% annually; management plans higher A&P (target 13% of revenues from 2026), a €500m productivity program through 2028 and has €3bn raised from a November bond under an €8bn MTN programme (S&P BBB, Moody’s Baa2). Analysts view the standalone structure as positive for focused capital allocation though some expect a more conservative ~3% base-case growth; the strong bond demand and early positive trading suggest investor appetite but execution on growth in markets like China and India will be key.

Analysis

Market structure: TMICC’s standalone listing increases clarity of cash flows and should concentrate branded-ice-cream demand onto a pure-play with 21% share vs Froneri’s 11%, improving pricing optionality in developed markets where 65% of sales lie. Greater A&P (target 13% from 2026) and a €500m productivity plan imply 100–200bp potential EBITDA margin expansion over 2–3 years if volume growth ≥3.5%; conversely, Unilever (UL) may face short-term selling pressure as it trims a 19.9% stake over five years.

Risk assessment: Tail risks include a major food-safety recall, a synchronous global slowdown reducing out‑of‑home demand (40% of sales), and rapid Unilever stake disposal compressing multiples; any of these could shave 20–40% from equity value. Short-term (days–weeks) expect IPO pop/mean-reversion; medium-term (3–12 months) hinge on H1 results and early A&P ROI; long-term (2–5 years) depends on EM execution in China/India and delivery of €500m savings.

Trade implications: Primary trade is a measured long in TMICC equity sized 2–3% of risk budget with a 12‑month upside target +20–30% conditional on organic growth ≥3.5% and EBITDA margin +150bps; hedge with a 0.5–1% short in UL to offset parent-driven macro/FX exposure. Use options: buy 12‑month 25‑delta call spreads (debit-limited) or sell 6‑month 10% OTM cash‑secured puts to acquire stock at a discount; buy 5‑year TMICC IG bonds if spreads >225bps vs Bunds.

Contrarian angles: Consensus assumes smooth A&P payback and EM scale-up; that’s underpriced risk—if TMICC fails to arrest volume erosion in China/India within two quarters, re-rating could be swift. Conversely, investors underappreciate the bond market signal: €3bn issuance 7x oversubscribed suggests credit markets already price low financing risk, making selective credit longs asymmetric vs equity downside.

Key Decisions for Investors

• Establish a 2–3% long position in TMICC equity (ticker: TMICC) within 2 weeks; target 12‑month upside +20–30% if organic sales ≥3.5% and EBITDA margin expands ≥150bps; set hard stop-loss at -12% or reassess if volume growth <1% for two consecutive quarters.
• Implement a relative-value hedge: pair long TMICC 2% with short UNILEVER (UL) 0.5–1% to neutralize FX/parent de‑leveraging risk; reduce UL short if Unilever stake sales are announced with clear lock‑up/sale timetable.
• Options: buy 12‑month 25‑delta call spreads sized to represent 1–1.5% portfolio exposure (limits downside) and/or sell 6‑month cash‑secured 10% OTM puts to collect premium and potentially acquire TMICC at a ~10% discount; roll if premium < target or implied vol rises >30% vs spot.
• Credit: buy TMICC/Magnum 5‑year senior bonds if spread ≥225bps over German Bunds (or ≥200bps over comparable IG reference) to capture carry; scale in up to 3% portfolio allocation and hedge duration if inflation expectations rise >50bps.